Skip to main content
Top
Published in: International Journal of Clinical Oncology 1/2015

01-02-2015 | Original Article

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Authors: Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya, Yoshiyuki Osamura, Shin-etsu Kamata, Kouki Miura, Chihiro Fushimi, Hideaki Takahashi, Daisuke Kawakita, Seiji Kishimoto, Toshitaka Nagao

Published in: International Journal of Clinical Oncology | Issue 1/2015

Login to get access

Abstract

Background

Salivary duct carcinoma (SDC) is a highly aggressive disease which often metastasizes to distant sites, and there is no established standard therapy for this systemic disease. Given that SDC is biologically similar to breast and prostate cancer, anti-androgenic receptor (AR) and anti-human epidermal growth factor receptor 2 (HER2) therapies have the potential to exert effects, not only on patients with breast and prostate cancer but also on those with SDC.

Methods

The expression levels of HER2, epidermal growth factor receptor (EGFR), Ki-67, and AR were assessed in 32 patients with SDC, and their correlations with overall survival (OS) and disease-free survival (DFS) were analyzed retrospectively. SDC was classified into five subtypes using a method similar to that used for breast cancer.

Results

Anti-AR, HER2, and EGFR were positive in 23 (71.9 %), 14 (43.8 %), and 26 (81.3 %) cases, respectively. One or more of these 3 factors were positive in 30 (93.8 %) cases. The Ki-67 labeling index was greater than 15 % in all cases. While molecular status did not correlate with OS, EGFR and AR positivity were significantly associated with DFS in univariate analysis. Multivariate analysis revealed that EGFR was the only independent predictor of DFS.

Conclusions

The statuses of some molecules are useful to predict DFS in patients with SDC. Ki-67 overexpression suggests that cytotoxic agents are effective for SDC. Since the majority of SDCs express AR, HER2, and/or EGFR, assessing and targeting these molecules are promising strategies to improve the prognosis of unresectable, metastatic or recurrent SDC, and a classification system according to the molecular expression status may be useful to select appropriate therapy.
Literature
1.
go back to reference Kleinsasser O, Klein HJ, Hübner G (1968) Salivary duct carcinomas: a group of salivary gland tumors analogous to ductal carcinoma of the breast. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192:100–105PubMedCrossRef Kleinsasser O, Klein HJ, Hübner G (1968) Salivary duct carcinomas: a group of salivary gland tumors analogous to ductal carcinoma of the breast. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192:100–105PubMedCrossRef
2.
go back to reference Seifert G, Batsakis JG, Brocheriou C et al (eds) (1991) World Health Organisation. Histological typing of salivary gland tumors, 2nd edn. Springer, New York Seifert G, Batsakis JG, Brocheriou C et al (eds) (1991) World Health Organisation. Histological typing of salivary gland tumors, 2nd edn. Springer, New York
3.
go back to reference Barnes L, Eveson W, Reichart P et al (eds) (2005) World Health Organization classification of tumours, pathology and genetics of head and neck tumours. IARC Press Lyon, France Barnes L, Eveson W, Reichart P et al (eds) (2005) World Health Organization classification of tumours, pathology and genetics of head and neck tumours. IARC Press Lyon, France
4.
go back to reference Lewis JE, McKinney BC, Weiland LH et al (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef Lewis JE, McKinney BC, Weiland LH et al (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef
5.
go back to reference Williams MD, Roberts D, Blumenschein GR Jr et al (2007) Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31:1645–1652PubMedCrossRef Williams MD, Roberts D, Blumenschein GR Jr et al (2007) Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31:1645–1652PubMedCrossRef
6.
go back to reference Guzzo M, Di Palma S, Grandi C et al (1997) Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19:126–133PubMedCrossRef Guzzo M, Di Palma S, Grandi C et al (1997) Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19:126–133PubMedCrossRef
7.
go back to reference Jaehne M, Roeser K, Jaekel T et al (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef Jaehne M, Roeser K, Jaekel T et al (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef
8.
go back to reference Adelstein DJ, Koyfman SA, El-Naggar AK et al (2012) Biology and management of salivary gland cancers. Semin Radiat Oncol 22:245–253PubMedCrossRef Adelstein DJ, Koyfman SA, El-Naggar AK et al (2012) Biology and management of salivary gland cancers. Semin Radiat Oncol 22:245–253PubMedCrossRef
9.
go back to reference Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCentralPubMedCrossRef Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCentralPubMedCrossRef
10.
go back to reference Lagha A, Chraiet N, Ayadi M et al (2012) Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 4:4–19CrossRef Lagha A, Chraiet N, Ayadi M et al (2012) Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 4:4–19CrossRef
11.
go back to reference Nagao T, Sato E, Inoue R et al (2012) Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem 45:269–282PubMedCentralPubMedCrossRef Nagao T, Sato E, Inoue R et al (2012) Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem 45:269–282PubMedCentralPubMedCrossRef
12.
go back to reference Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607–617PubMedCrossRef Castellano I, Allia E, Accortanzo V et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607–617PubMedCrossRef
13.
go back to reference Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCentralPubMedCrossRef Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCentralPubMedCrossRef
14.
go back to reference Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1):1–11PubMedCrossRef Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1):1–11PubMedCrossRef
15.
go back to reference Hoang MP, Callender DL, Sola Gallego JJ et al (2001) Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 19:865–871PubMed Hoang MP, Callender DL, Sola Gallego JJ et al (2001) Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 19:865–871PubMed
16.
go back to reference Russell PJ, Bennett S, Stricker P (1998) Growth factor involvement in progression of prostate cancer. Clin Chem 44:705–723PubMed Russell PJ, Bennett S, Stricker P (1998) Growth factor involvement in progression of prostate cancer. Clin Chem 44:705–723PubMed
17.
go back to reference Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491–1498CrossRef Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491–1498CrossRef
18.
go back to reference Nagao T, Gaffey TA, Visscher DW et al (2004) Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol 28:319–326PubMedCrossRef Nagao T, Gaffey TA, Visscher DW et al (2004) Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol 28:319–326PubMedCrossRef
19.
go back to reference Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRef Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRef
20.
go back to reference Batsakis JG, El-Naggar AK, Luna MA (1992) Adenocarcinoma, not otherwise specified: a diminishing group of salivary carcinomas. Ann Otol Rhinol Laryngol 101:102–104PubMedCrossRef Batsakis JG, El-Naggar AK, Luna MA (1992) Adenocarcinoma, not otherwise specified: a diminishing group of salivary carcinomas. Ann Otol Rhinol Laryngol 101:102–104PubMedCrossRef
21.
go back to reference Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCentralPubMedCrossRef Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCentralPubMedCrossRef
22.
go back to reference Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
23.
go back to reference Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef
24.
go back to reference Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef
25.
go back to reference Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664PubMedCentralPubMedCrossRef Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki-67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664PubMedCentralPubMedCrossRef
26.
go back to reference Takeda H, Akakura K, Masai M et al (1996) Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77:934–940PubMedCrossRef Takeda H, Akakura K, Masai M et al (1996) Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77:934–940PubMedCrossRef
27.
go back to reference Ruizeveld de Winter JA, Trapman J, Vermey M et al (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 39:927–936PubMedCrossRef Ruizeveld de Winter JA, Trapman J, Vermey M et al (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 39:927–936PubMedCrossRef
28.
go back to reference van der Hulst RW, van Krieken JH, van der Kwast TH et al (1994) Partial remission of parotid gland carcinoma after goserelin. Lancet 344:817PubMedCrossRef van der Hulst RW, van Krieken JH, van der Kwast TH et al (1994) Partial remission of parotid gland carcinoma after goserelin. Lancet 344:817PubMedCrossRef
29.
go back to reference Locati LD, Bossi B, Rinaldi GR et al (2003) Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann Oncol 14(Suppl 4):126 Locati LD, Bossi B, Rinaldi GR et al (2003) Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann Oncol 14(Suppl 4):126
30.
go back to reference Locati LD, Quattrone P, Bossi P et al (2003) A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14:1327–1328PubMedCrossRef Locati LD, Quattrone P, Bossi P et al (2003) A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14:1327–1328PubMedCrossRef
31.
go back to reference Jaspers HC, Verbist BM, Schoffelen R et al (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):e473–e476PubMedCrossRef Jaspers HC, Verbist BM, Schoffelen R et al (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):e473–e476PubMedCrossRef
32.
go back to reference Kumar B, Cordell KG, Lee JS et al (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128–3137PubMedCentralPubMedCrossRef Kumar B, Cordell KG, Lee JS et al (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128–3137PubMedCentralPubMedCrossRef
33.
go back to reference Schlomm T, Kirstein P, Iwers L et al (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13:6579–6584PubMedCrossRef Schlomm T, Kirstein P, Iwers L et al (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13:6579–6584PubMedCrossRef
34.
go back to reference Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578PubMedCrossRef Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574–578PubMedCrossRef
35.
go back to reference De Dosso S, Mazzucchelli L, Ghielmini M et al (2009) Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori 95:378–381PubMed De Dosso S, Mazzucchelli L, Ghielmini M et al (2009) Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori 95:378–381PubMed
36.
go back to reference Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol, ASCO Annual Meeting Proceedings, 23(16S), Part I of II (June 1 Supplement):5532 Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol, ASCO Annual Meeting Proceedings, 23(16S), Part I of II (June 1 Supplement):5532
37.
go back to reference Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef
38.
go back to reference Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
39.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRef Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRef
40.
go back to reference Gatzemeier U, Groth G, Butts C et al (2004) Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19–27PubMedCrossRef Gatzemeier U, Groth G, Butts C et al (2004) Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19–27PubMedCrossRef
41.
42.
go back to reference Safran H, Iannitti D, Ramanathan R et al (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22:706–712PubMedCrossRef Safran H, Iannitti D, Ramanathan R et al (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22:706–712PubMedCrossRef
43.
go back to reference Hussain MH, MacVicar GR, Petrylak DP et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218–2224PubMedCrossRef Hussain MH, MacVicar GR, Petrylak DP et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218–2224PubMedCrossRef
44.
go back to reference Nabili V, Tan JW, Bhuta S et al (2007) Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29:907–912PubMedCrossRef Nabili V, Tan JW, Bhuta S et al (2007) Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29:907–912PubMedCrossRef
45.
go back to reference Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123:250–252PubMedCrossRef Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123:250–252PubMedCrossRef
46.
go back to reference Prat A, Parera M, Reyes V et al (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683PubMedCrossRef Prat A, Parera M, Reyes V et al (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683PubMedCrossRef
47.
go back to reference Sharon E, Kelly RJ, Szabo E (2010) Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol 26:2–12 Sharon E, Kelly RJ, Szabo E (2010) Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol 26:2–12
48.
go back to reference Kaidar-Person O, Billan S, Kuten A (2011) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29:704–706PubMedCrossRef Kaidar-Person O, Billan S, Kuten A (2011) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29:704–706PubMedCrossRef
49.
go back to reference Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183PubMedCrossRef Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183PubMedCrossRef
50.
go back to reference Tanei T, Shimomura A, Shimazu K et al (2011) Prognostic significance of Ki-67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 37:155–161PubMedCrossRef Tanei T, Shimomura A, Shimazu K et al (2011) Prognostic significance of Ki-67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 37:155–161PubMedCrossRef
51.
go back to reference Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A et al (1997) Salivary duct carcinoma: clinicopathological and immunohistochemical studies. Am J Clin Pathol 109:75–84 Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A et al (1997) Salivary duct carcinoma: clinicopathological and immunohistochemical studies. Am J Clin Pathol 109:75–84
52.
go back to reference Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCentralPubMedCrossRef Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCentralPubMedCrossRef
53.
go back to reference Banerji S, Cibulskis K, Rangel-Escareno C et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405–409PubMedCentralPubMedCrossRef Banerji S, Cibulskis K, Rangel-Escareno C et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405–409PubMedCentralPubMedCrossRef
Metadata
Title
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
Authors
Tatsuo Masubuchi
Yuichiro Tada
Shin-ichiro Maruya
Yoshiyuki Osamura
Shin-etsu Kamata
Kouki Miura
Chihiro Fushimi
Hideaki Takahashi
Daisuke Kawakita
Seiji Kishimoto
Toshitaka Nagao
Publication date
01-02-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0674-6

Other articles of this Issue 1/2015

International Journal of Clinical Oncology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine